Morse Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $693K | Buy |
897
+103
| +13% | +$78.9K | 0.14% | 112 |
|
|
2025
Q4 | $613K | Buy |
794
+92
| +13% | +$62.5K | 0.12% | 117 |
|
|
2025
Q3 | $395K | Sell |
702
-93
| -12% | -$52.6K | 0.08% | 124 |
|
|
2025
Q2 | $417K | Sell |
795
-3,324
| -81% | -$1.86M | 0.09% | 128 |
|
|
2025
Q1 | $2.61M | Buy |
4,119
+2,264
| +122% | +$1.56M | 0.66% | 43 |
|
|
2024
Q4 | $1.32M | Sell |
1,855
-2,952
| -61% | -$2.48M | 0.3% | 73 |
|
|
2024
Q3 | $5.05M | Buy |
4,807
+43
| +0.9% | +$47.9K | 1.09% | 23 |
|
|
2024
Q2 | $5.01M | Buy |
4,764
+180
| +4% | +$174K | 1.21% | 25 |
|
|
2024
Q1 | $4.41M | Buy |
4,584
+47
| +1% | +$44.7K | 1.13% | 31 |
|
|
2023
Q4 | $3.98M | Buy |
4,537
+430
| +10% | +$354K | 1.17% | 29 |
|
|
2023
Q3 | $3.38M | Buy |
4,107
+183
| +5% | +$144K | 1.07% | 33 |
|
|
2023
Q2 | $2.82M | Buy |
3,924
+161
| +4% | +$124K | 0.86% | 41 |
|
|
2023
Q1 | $3.09M | Buy |
3,763
+75
| +2% | +$56.6K | 1.04% | 33 |
|
|
2022
Q4 | $2.66M | Buy |
3,688
+8
| +0.2% | +$5.9K | 0.97% | 34 |
|
|
2022
Q3 | $2.54M | Sell |
3,680
-128
| -3% | -$80.6K | 0.96% | 32 |
|
|
2022
Q2 | $2.25M | Buy |
3,808
+509
| +15% | +$331K | 0.72% | 47 |
|
|
2022
Q1 | $2.3M | Buy |
3,299
+320
| +11% | +$202K | 0.57% | 51 |
|
|
2021
Q4 | $1.88M | Sell |
2,979
-115
| -4% | -$70.7K | 0.42% | 66 |
|
|
2021
Q3 | $1.87M | Buy |
3,094
+1,724
| +126% | +$1.07M | 0.45% | 62 |
|
|
2021
Q2 | $765K | Buy |
1,370
+654
| +91% | +$331K | 0.18% | 98 |
|
|
2021
Q1 | $339K | Buy |
716
+25
| +4% | +$12.2K | 0.09% | 129 |
|
|
2020
Q4 | $334K | Sell |
691
-95
| -12% | -$51.3K | 0.09% | 116 |
|
|
2020
Q3 | $440K | Hold |
786
| – | – | 0.14% | 95 |
|
|
2020
Q2 | $490K | Buy |
786
+100
| +15% | +$56.8K | 0.17% | 87 |
|
|
2020
Q1 | $335K | Buy |
+686
| New | +$283K | 0.16% | 87 |
|
|
2019
Q3 | – | Sell |
-5,442
| Closed | -$1.7M | – | 135 |
|
|
2019
Q2 | $1.7M | Sell |
5,442
-3,748
| -41% | -$1.25M | 0.5% | 57 |
|
|
2019
Q1 | $3.77M | Sell |
9,190
-148
| -2% | -$60.9K | 1.13% | 26 |
|
|
2018
Q4 | $3.49M | Buy |
9,338
+156
| +2% | +$57.1K | 1.24% | 25 |
|
|
2018
Q3 | $3.71M | Buy |
9,182
+3,127
| +52% | +$1.19M | 0.98% | 30 |
|
|
2018
Q2 | $2.09M | Sell |
6,055
-2,050
| -25% | -$641K | 0.57% | 51 |
|
|
2018
Q1 | $2.79M | Buy |
8,105
+30
| +0.4% | +$10.4K | 0.77% | 41 |
|
|
2017
Q4 | $3.04M | Sell |
8,075
-1,608
| -17% | -$651K | 0.84% | 38 |
|
|
2017
Q3 | $4.33M | Buy |
9,683
+376
| +4% | +$179K | 1.29% | 24 |
|
|
2017
Q2 | $4.57M | Buy |
9,307
+700
| +8% | +$306K | 1.49% | 17 |
|
|
2017
Q1 | $3.33M | Buy |
+8,607
| New | +$3.19M | 1.14% | 26 |
|
Other funds holding REGN
VCM
N
Morse Asset Management's REGN Position: Q1 2026 in Review
Morse Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 13% in Q1 2026, buying an estimated $78.9K and bringing the position to 897 shares worth $693K. The position accounts for 0.14% of the portfolio, ranked #112.
Morse Asset Management first reported a position in REGN in Q1 2017 and has held it in 35 quarters since. The position peaked at $5.05M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Morse Asset Management held 897 shares of Regeneron Pharmaceuticals worth $693K as of Q1 2026.
- Morse Asset Management bought 103 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $78.9K.
- Regeneron Pharmaceuticals made up 0.14% of Morse Asset Management's portfolio in Q1 2026, its #112 holding.
- Morse Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 35 quarters since.
- Morse Asset Management's Regeneron Pharmaceuticals position peaked at $5.05M in Q3 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Morse Asset Management's 13F filing for Q1 2026, filed 14 May 2026.